Among the clinical subgroups, BLCA survival had the best overall prognosis in the GPR-low + TME-high group and the worst prognosis in the GPR-high + TME-low group (Figure 3a). The gene discussed is ALDH18A1; the disease is bladder transitional cell carcinoma.